Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT03109769 Completed - Clinical trials for Orthodontic Appliance Complication

The Effect of Using Mobile Applications for Improving Oral Hygiene

Start date: February 12, 2016
Phase: N/A
Study type: Interventional

The study aims to investigate the effect of the use of mobile phone application sending reminders to patients with orthodontic fixed appliances on oral hygiene.

NCT ID: NCT03109574 Completed - Clinical trials for Central Venous Catheter

Access in Dialysis for Better Outcomes in Patient Therapy

ADOPT
Start date: August 29, 2016
Phase: N/A
Study type: Interventional

This is a prospective, multi-center health economic study in Canada. Participants will be randomly assigned to receive either the study or control dialysis catheter. The primary objective is to evaluate resource utilization in Ontario related to hemodialysis catheter placement including tissue plasminogen activator (tPA) usage, catheter exchange rates, catheter patency, and missed dialysis days.

NCT ID: NCT03109431 Completed - HIV Clinical Trials

Stepped Care for Youth Living With HIV

Start date: May 6, 2017
Phase: N/A
Study type: Interventional

Optimizing the HIV Treatment Continuum with a Stepped Care Model for Youth Living with HIV (YLH) aims to achieve viral suppression among YLH. A cohort of 220 YLH will be identified in Los Angeles, CA and New Orleans, LA and recruited into a randomized controlled trial (RCT) with reassessments every 4 months over a 12 month follow-up period. The goal is to optimize the HIV Treatment Continuum over 12 months. YLH will be randomized into one of two study conditions: 1) Enhanced Standard Care Condition (n=110); or 2) Stepped Care (n=110). The Enhanced Standard Care condition will consist of an Automated Messaging and Monitoring Intervention (AMMI) with daily motivational, instructional and referral text messaging, and a brief weekly monitoring survey. The Stepped Care Condition will consist of three levels. Level 1 is the Enhanced Standard Care Condition. Level 2 is the Enhanced Standard Care Condition plus peer support using social media. Level 3 is the Enhanced Standard Care Condition and peer support plus coaching, which will be delivered primarily through electronic means (e.g., social media, text messaging, email, phone). All participants in the Stepped Care Condition begin at Level 1 but if they fail to have a suppressed viral load at any four-month assessment point, their intervention level will increase by one step until reaching Level 3.

NCT ID: NCT03109392 Completed - Clinical trials for Patients With Indication for Flexible Bronchoscopy

A Randomized Trial of 4% Nebulized Lignocaine vs. 10% Lignocaine Spray in Patients Undergoing Flexible Bronchoscopy

Start date: May 1, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

Flexible bronchoscopy is common procedure used in the diagnosis and treatment of a variety of tracheobronchial diseases. During routine diagnostic flexible bronchoscopy, the most distressing symptom experienced by the patients is a cough, and control of a cough is vital for a successful procedure. The investigators hypothesized that either nebulized lignocaine or lignocaine spray given alone prior to flexible bronchoscopy for inducing topical anesthesia will have similar efficacy compared to the combination of the two agents.

NCT ID: NCT03109379 Completed - Clinical trials for Idiopathic Overactive Bladder With Urinary Incontinence

Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder

Start date: April 4, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine if TAR-302-5018, an investigational drug-delivery system, is safe and tolerable in patients with idiopathic overactive bladder and urinary incontinence.

NCT ID: NCT03109353 Completed - Clinical trials for Cutaneous T-Cell Lymphoma, Unspecified

Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease

Start date: September 20, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Extracorporeal photopheresis (ECP), is commonly used for the treatment of cutaneous T-cell lymphoma (CTCL) and chronic graft-versus-host disease. ECP (cGVHD) is an immune modulating treatment. White blood cells from the patient are standardized activated by a photosensitizer psoralen (8-MOP) and irradiated with visible ultraviolet light (UV-A). The purpose is to induce programmed cell death (apoptosis). Disadvantage of current treatment is that 8-MOP targets both diseased and normal cells with no selectivity. The purpose of this study is to improve the current ECP technology using aminolevulinic acid (ALA) and UV light. ECP will be carried out in conventional manner except that 8-MOP will be replaced with ALA. Systemic ALA / UV light is already approved and used in the detection and treatment of disease in humans. The primary objective is to assess its safety and tolerability after single and multiple treatment in patients with CTCL or cGvHD.

NCT ID: NCT03109249 Completed - Clinical trials for Recurrent or Metastatic Breast Cancer

Pharmacokinetic Study of SPARC1613 and reference1613 in Subjects With Locally Recurrent or Metastatic Breast Cancer

Start date: January 14, 2017
Phase: Phase 1
Study type: Interventional

SPARC1613 is chemotherapeutic agent with a wide spectrum of anti-tumor activity. It is used extensively in the treatment of advanced carcinomas of the breast, ovaries, lung, and other solid tumors.This is pharmacokinetic study of SPARC1613 and Reference1613.

NCT ID: NCT03109158 Completed - Clinical trials for Carcinoma, Squamous Cell of Head and Neck

NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Start date: March 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Part 1 of this study will establish a recommended Phase II (RPII) dose for the triplet combination of NC-6004 plus 5-Fluorouracil (5-FU) and cetuximab. Part 2 will provide the efficacy signal of the triplet combination in this patient population.

NCT ID: NCT03109080 Completed - Clinical trials for Radiotherapy Side Effect

Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)

RadioPARP
Start date: July 24, 2017
Phase: Phase 1
Study type: Interventional

A Phase I of Olaparib with Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced or Metastatic TNBC (triple negative breast cancer) or Patient With Operated TNBC with Residual Disease.

NCT ID: NCT03109002 Completed - Clinical trials for Depressive Disorder, Treatment-Resistant

An Epidemiology Study of Treatment Resistant Depression in the United States (US)

Start date: January 15, 2017
Phase:
Study type: Observational

The purpose of this study is to describe the epidemiology of Treatment Resistant Depression (TRD) in the US, including the population incidence of TRD, and TRD as a proportion of Pharmacologically Treated Depression (PTD), and stratify the estimates by sex and age group, with separate estimates for the Medicaid population, the Medicare population, and the privately insured population. Anonymized participants data will be used for the analysis.